Peptide describes a type of molecule, not a level of evidence. Some peptide-based medicines are authorised for specific conditions. Other compounds promoted for healing, muscle, weight loss or longevity have little relevant human evidence and uncertain product quality.
Start with the exact substance
Write down the generic name, formulation, route and claimed use. A category such as “recovery peptide” can hide major differences between an authorised medicine, an experimental compound, a cosmetic ingredient and a vial sold as research material.
Approval is specific
Medicine authorisation applies to a particular product, indication, population, dose and route. Approval of one peptide-based medicine does not validate another compound with a similar mechanism. In the UK, consult official product information and a qualified prescriber rather than a seller’s interpretation of regulation.
A useful evidence ladder
- Regulatory assessment and clinical guidance: useful for approved uses, contraindications and monitored safety.
- Systematic reviews and well-designed human trials: check whether the participants and outcomes match the claim.
- Early human pharmacology: can show biological activity without proving patient benefit.
- Animal and laboratory studies: generate hypotheses but cannot establish a human treatment.
- Testimonials and influencer content: cannot separate treatment effects from chance, expectation or selective reporting.
Product quality is part of the evidence
A paper about a known research material cannot prove the contents of an online vial. Identity, sterility, concentration, impurities, storage and traceability all matter. “Research grade”, “pharmaceutical grade” and a seller-provided certificate are not substitutes for medicine authorisation.
Red flags
- Guaranteed healing, fat loss, muscle gain or anti-ageing.
- Dosage instructions alongside “not for human use”.
- No regulated prescriber or pharmacy.
- Evidence consisting mainly of mechanisms, animals or testimonials.
- Bundles or stacks designed to treat several unrelated goals.
Use the site
- Five-minute peptide evidence checker
- UK legal and regulatory questions
- Peptide evidence and approval overview
- BPC-157 evidence review
If you encounter a suspicious seller
You can report a suspicious online medicine seller to the MHRA. Side effects involving medicines or devices can be reported through the Yellow Card scheme.